Stock LOGC LOGICBIO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News LogicBio Therapeutics, Inc.

Equities

LOGC

US54142F1021

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CANbridge Pharmaceuticals Inc. Announces Update on Collaborations with the Umass Chan Medical School and with Logicbio Therapeutics
CI
LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from S&P TMI Index
CI
Alexion AstraZeneca Rare Disease Completes Acquisition of LogicBio Therapeutics
AQ
LOGICBIO THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
LogicBio Therapeutics, Inc. Announces Management Changes
CI
AstraZeneca Unit Completes Acquisition of LogicBio Therapeutics
MT
LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from NASDAQ Composite Index
CI
Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders.
CI
LogicBio Therapeutics : Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet - Definitive merger agreement with Alexion, AstraZeneca Rare Disease, to acquire LogicBio with transaction - Form 8-K
PU
LOGICBIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
LogicBio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
LOGICBIO THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
LogicBio Therapeutics: Q3 Earnings Snapshot
AQ
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Revenue $2.7M
MT
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Loss $-0.18
MT
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
PR
LOGICBIO THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC
BU
LOGICBIO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
LogicBio Therapeutics, Inc. and CANbridge Care Pharma Hong Kong Limited Enter into the Amended and Restated Exclusive Research Collaboration, License and Option Agreement
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LOGC Stock
  4. News LogicBio Therapeutics, Inc.